The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis-Reference-Cited by-同舟云学术

The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis

Published:2020-09 Issue:9 Volume:26 Page:1747-1756
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Arnold Staci D.,Brazauskas Ruta,He Naya,Li Yimei,Hall Matt,Atsuta Yoshiko,Dalal Jignesh,Hahn Theresa,Khera Nandita,Bonfim Carmem,Hashmi Shahrukh,Parsons Susan,Wood William A.,Steinberg Amir,Freytes César O.,Dandoy Christopher E.,Marks David I.,Lazarus Hillard M.,Abdel-Azim Hisham,Bitan Menachem,Diaz Miguel Angel,Olsson Richard F.,Gergis Usama,Seber Adriana,Wirk Baldeep,LeMaistre C. Fred,Ustun Celalettin,Duncan Christine,Rizzieri David,Szwajcer David,Fagioli Franca,Frangoul Haydar,Knight Jennifer M.,Kamble Rammurti T.,Mehta Paulette,Schears Raquel,Satwani Prakash,Pulsipher Michael A.,Aplenc Richard,Saber Wael

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference30 articles.

1. Current allogeneic hematopoietic stem cell transplantation for pediatric acute lymphocytic leukemia: success, failure and future perspectives-a single-center experience, 2008 to 2016;Yanir;Biol Blood Marrow Transplant,2018

2. Allogeneic stem cell transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 BFM and 2007 International BFM Studies: impact of disease risk on outcomes;Dalle;Biol Blood Marrow Transplant,2018

3. The evolution of allogeneic stem cell transplant for children and adolescents with acute myeloid leukemia;Flower;Clin Adv Hematol Oncol,2017

4. Alternative donor hematopoietic cell transplantation conditioned with myeloablative busulfan, fludarabine, and melphalan is well tolerated and effective against high-risk myeloid malignancies;Katsanis;J Pediatr Hematol Oncol,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial;Transplantation and Cellular Therapy;2023-12

2. Costs of matched-sibling, unrelated, and haploidentical hematopoietic cell transplantation and risk factors for greater financial burden — a Brazilian FACT-accredited single-center analysis;Annals of Hematology;2022-09-12

3. HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients;Pediatric Transplantation;2022-01-28

4. Length of Stay and Health Care Utilization Among Pediatric Autologous Hematopoietic Cell Transplantation Recipients;Transplantation and Cellular Therapy;2021-07

5. The wider perspective: cord blood banks and their future prospects;British Journal of Haematology;2021-04-20